摘要
目的探究美托洛尔联合依那普利治疗风湿性心脏病慢性心力衰竭的效果及安全性。方法选取2014年5月至2017年4月在我院接受治疗的风湿性心脏病慢性心力衰竭患者84例为研究对象,随机将其分为常规组(42例)与干预组(42例)。常规组给予依那普利治疗,干预组给予美托洛尔联合依那普利治疗。比较两组的治疗效果、治疗前、后心功能与不良反应发生情况。结果干预组的治疗总有效率显著高于常规组(P<0.05)。治疗后,干预组的左心房内径、左心室舒张末期内径、左心室射血分数均优于常规组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论美托洛尔联合依那普利治疗风湿性心脏病慢性心力衰竭能够有效改善患者的心功能,疗效显著且安全性较高。
Objective To investigate the efficacy and safety of metoprolol combined with enalapril in the treatment of rheumatic heart disease and chronic heart failure.Methods A total of 84 patients with rheumatic heart disease and chronic heart failure treated in our hospital from May 2014 to April 2017 were selected as the research subjects and randomly divided into routine group(42 cases)and intervention group(42 cases).The routine group was given enalapril,and the intervention group was given metoprolol combined with enalapril.The treatment effects,cardiac function before and after treatment and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the intervention group was significantly higher than that in the routine group(P<0.05).After treatment,the left atrial diameter,left ventricular end diastolic diameter and left ventricular ejection fraction of the intervention group were better than those of the routine group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion Metoprolol combined with enalapril in the treatment of rheumatic heart disease and chronic heart failure can effectively improve the patients'heart function,with significant curative effect and high safety.
作者
张艳
ZHANG Yan(Nanyang Third People's Hospital,Nanyang 473000,China)
出处
《临床医学研究与实践》
2020年第8期43-44,共2页
Clinical Research and Practice
